March 30, 2020

Sigilon Therapeutics – $80.3 Million

Sigilon Therapeutics

Cambridge, Mass ; 03/18/2020

Amount Funded: $80.3 Million

Type: Series B

Investor(s):  Canada Pension Plan Investment Board, Longevity Vision Fund, BlackRock, Flagship Pioneering, Eli Lilly, others.

Total Funding to Date: $195 Million

Company Description: Sigilon Therapeutics is developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s therapeutics consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

What funding will be used for: “The funding will support the first-in-human clinical trial of Sigilon’s novel encapsulated cell therapy for hemophilia A, expected to begin in the first half of 2020, as well as continued advancement and expansion of Sigilon’s programs in rare blood disorders, lysosomal diseases and endocrine and immune disorders.”

Quotes:

“Sigilon is driven to liberate patients from the fear of living with serious chronic diseases, and from alternative therapeutic approaches. Our Shielded Living Therapeutics platform is designed to give patients who have chronic diseases a convenient, safe, long-term therapeutic benefit. We believe encapsulating engineered human cells in our proprietary matrix will enable us to deliver controlled doses of therapeutic proteins without the need for immunosuppression and without the risks associated with modifying patients’ genomes. We are pleased to welcome an exceptional group of investors who share our vision of offering more hope and less fear to patients and their caregivers as we enter the clinic with our lead program and continue to advance our other programs toward the clinic.”

-Rogerio Vivaldi, M.D., president/CEO. Sigilon Therapeutics

Notes:

Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.

 

StartupsOne

StartupsOne features relevant, focused news on venture capital funding of technology oriented startup businesses based in North America.

View all posts by StartupsOne →